Patents by Inventor Fucheng Qu

Fucheng Qu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GLUCAGON-LIKE PEPTIDE1 RECEPTOR AGONISTS
    Publication number: 20230250092
    Abstract: In an embodiment, the present invention provides a compound of the formula: or a pharmaceutically acceptable salt thereof, and methods of using this compound for treating type II diabetes mellitus.
    Type: Application
    Filed: March 31, 2023
    Publication date: August 10, 2023
    Inventors: David Andrew COATES, Todd FIELDS, Joseph Daniel HO, Fucheng QU
  • Glucagon-like peptide1 receptor agonists
    Patent number: 11655242
    Abstract: In an embodiment, the present invention provides a compound of the formula: or a pharmaceutically acceptable salt thereof, and methods of using this compound for treating type II diabetes mellitus.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: May 23, 2023
    Assignee: Eli Lilly and Company
    Inventors: David Andrew Coates, Todd Fields, Joseph Daniel Ho, Fucheng Qu
  • GLUCAGON-LIKE PEPTIDE1 RECEPTOR AGONISTS
    Publication number: 20200407347
    Abstract: In an embodiment, the present invention provides a compound of the formula: or a pharmaceutically acceptable salt thereof, and methods of using this compound for treating type II diabetes mellitus.
    Type: Application
    Filed: June 19, 2020
    Publication date: December 31, 2020
    Inventors: David Andrew COATES, Todd FIELDS, Joseph Daniel HO, Fucheng QU
  • Pyrazole compounds
    Patent number: 9296775
    Abstract: The present invention provides a compound of Formula II: wherein X represents the following: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: March 29, 2016
    Assignee: ELI LILLY AND COMPANY
    Inventor: Fucheng Qu
  • NOVEL UREA COMPOUNDS
    Publication number: 20140296171
    Abstract: The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 17, 2014
    Publication date: October 2, 2014
    Inventor: Fucheng QU
  • Urea compounds
    Patent number: 8785404
    Abstract: The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 25, 2013
    Date of Patent: July 22, 2014
    Assignee: Eli Lilly and Company
    Inventor: Fucheng Qu
  • NOVEL PYRAZOLE COMPOUNDS
    Publication number: 20140162967
    Abstract: The present invention provides a compound of Formula II: wherein X represents the following: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 18, 2014
    Publication date: June 12, 2014
    Applicant: Eli Lilly and Company
    Inventor: Fucheng Qu
  • Pyrazole compounds
    Patent number: 8697849
    Abstract: The present invention provides a compound of Formula II: wherein X represents the following: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 2, 2013
    Date of Patent: April 15, 2014
    Assignee: Eli Lilly and Company
    Inventors: Fucheng Qu, Nathan Bryan Mantlo
  • NOVEL UREA COMPOUNDS
    Publication number: 20140100179
    Abstract: The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 25, 2013
    Publication date: April 10, 2014
    Applicant: Eli Lilly and Company
    Inventor: Fucheng QU
  • NOVEL PYRAZOLE COMPOUNDS
    Publication number: 20130303471
    Abstract: The present invention provides a compound of Formula II: wherein X represents the following: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 2, 2013
    Publication date: November 14, 2013
    Applicant: Eli Lilly and Company
    Inventors: Fucheng QU, Nathan Bryan MANTLO
  • FXR agonists
    Patent number: 7846960
    Abstract: Compounds of formula wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.
    Type: Grant
    Filed: May 22, 2007
    Date of Patent: December 7, 2010
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Robert Anthony Doti, Michael James Genin, Peter Ambrose Lander, Tianwei Ma, Peter Rudolph Manninen, Jason Matthew Ochoada, Fucheng Qu, Lindsay Scott Stelzer, Ryan Edward Stites, Alan M. Warshawsky
  • FXR AGONISTS
    Publication number: 20090270460
    Abstract: Compounds of formula wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.
    Type: Application
    Filed: May 22, 2007
    Publication date: October 29, 2009
    Inventors: Michael Gregory Bell, Robert Anthony Doti, Michael James Genin, Peter Ambrose Lander, Tianwei Ma, Peter Rudolph Manninen, Jason Matthew Ochoada, Fucheng Qu, Lindsay Scott Stelzer, Ryan Edward Stites, Alan M. Warshawsky
  • L-beta-dioxolane uridine analogs and methods for treating and preventing virus infections
    Publication number: 20010018440
    Abstract: The present invention relates to the discovery that certain P-L-dioxolane nucleoside analogs which contain a uracil base, and preferably, a 5-halosubstituted uracil base, exhibit unexpectedly high activity against Epstein-Barr virus (EBV), Varciella-Zoster virus (VZV) and Herpes Virus 8 (HV-8). In particular, the compounds according to the present invention show potent inhibition of the replication of the virus (viral growth) in combination with very low toxicity to the host cells (i.e., animal or human tissue). Compounds are useful for treating EBV, VZV and HV-8 infections in humans.
    Type: Application
    Filed: January 19, 2001
    Publication date: August 30, 2001
    Applicant: Yale University and The University of Georgia Research Foundation, Inc.
    Inventors: Chung K. Chu, Yung-Chi Cheng, Fucheng Qu
  • L-&bgr;-dioxolane uridine analogs and their pharmaceutical compositions
    Patent number: 6274589
    Abstract: The present invention relates to the discovery that certain &bgr;-L-dioxolane nucleoside analogs which contain a uracil base, and preferably, a 5-halosubstituted uracil base, exhibit unexpectedly high activity against Epstein-Barr virus (EBV), Varciella-Zoster virus (VZV) and Herpes Virus 8 (HV-8). In particular, the compounds according to the present invention show potent inhibition of the replication of the virus (viral growth) in combination with very low toxicity to the host cells (i.e., animal or human tissue). Compounds are useful for treating EBV, VZV and HV-8 infections in humans.
    Type: Grant
    Filed: July 29, 1999
    Date of Patent: August 14, 2001
    Assignees: Yale University, The University of Georgia Research Foundation
    Inventors: Chung K. Chu, Yung-Chi Cheng, Fucheng Qu
  • L-.beta.-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
    Patent number: 6022876
    Abstract: The present invention relates to the discovery that certain .beta.-L-dioxolane nucleoside analogs which contain a uracil base, and preferably, a 5-halosubstituted uracil base, exhibit unexpectedly high activity against Epstein-Barr virus (EBV), Varciella-Zoster virus (VZV) and Herpes Virus 8 (HV-8). In particular, the compounds according to the present invention show potent inhibition of the replication of the virus (viral growth) in combination with very low toxicity to the host cells (i.e., animal or human tissue). Compounds are useful for treating EBV, VZV and HV-8 infections in humans.
    Type: Grant
    Filed: October 21, 1997
    Date of Patent: February 8, 2000
    Assignee: Yale University
    Inventors: Chung K. Chu, Fucheng Qu, Yung-Chi Cheng
  • L-.beta.-dioxolane uridine analog administration for treating Epstein-Barr virus infection
    Patent number: 5792773
    Abstract: The present invention relates to the discovery that certain .beta.-L-dioxolane nucleoside analogs which contain a uracil base, and preferably, a 5-halosubstituted uracil base, exhibit unexpectedly high activity against Epstein-Barr virus (EBV). In particular, the compounds according to the present invention show potent inhibition of the replication of the virus (viral growth) in combination with very low toxicity to the host cells (i.e., animal or human tissue). Compounds are useful for treating EBV infections in humans.
    Type: Grant
    Filed: November 15, 1996
    Date of Patent: August 11, 1998
    Assignees: Yale University, University of Georgia Research Foundation
    Inventors: Chung K. Chu, Yung-Chi Cheng, Fucheng Qu